000 | 01945 a2200553 4500 | ||
---|---|---|---|
005 | 20250517131441.0 | ||
264 | 0 | _c20170710 | |
008 | 201707s 0 0 eng d | ||
022 | _a1932-6203 | ||
024 | 7 |
_a10.1371/journal.pone.0168248 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aKazmierczak, Philipp M | |
245 | 0 | 0 |
_a68Ga-TRAP-(RGD)3 Hybrid Imaging for the In Vivo Monitoring of αvß3-Integrin Expression as Biomarker of Anti-Angiogenic Therapy Effects in Experimental Breast Cancer. _h[electronic resource] |
260 |
_bPloS one _c2016 |
||
300 |
_ae0168248 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aBevacizumab _xadministration & dosage |
650 | 0 | 4 |
_aBiomarkers, Tumor _xmetabolism |
650 | 0 | 4 |
_aBreast Neoplasms _xdiagnostic imaging |
650 | 0 | 4 | _aCell Line, Tumor |
650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
650 | 0 | 4 |
_aCell Survival _xdrug effects |
650 | 0 | 4 |
_aDrug Monitoring _xmethods |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aGallium Radioisotopes _xadministration & dosage |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aIntegrin alphaVbeta3 _xmetabolism |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aMice, SCID |
650 | 0 | 4 |
_aPositron Emission Tomography Computed Tomography _xmethods |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 | _aTumor Burden |
650 | 0 | 4 | _aXenograft Model Antitumor Assays |
700 | 1 | _aTodica, Andrei | |
700 | 1 | _aGildehaus, Franz-Josef | |
700 | 1 | _aHirner-Eppeneder, Heidrun | |
700 | 1 | _aBrendel, Matthias | |
700 | 1 | _aEschbach, Ralf S | |
700 | 1 | _aHellmann, Magdalena | |
700 | 1 | _aNikolaou, Konstantin | |
700 | 1 | _aReiser, Maximilian F | |
700 | 1 | _aWester, Hans-Jürgen | |
700 | 1 | _aKropf, Saskia | |
700 | 1 | _aRominger, Axel | |
700 | 1 | _aCyran, Clemens C | |
773 | 0 |
_tPloS one _gvol. 11 _gno. 12 _gp. e0168248 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1371/journal.pone.0168248 _zAvailable from publisher's website |
999 |
_c26711535 _d26711535 |